Evolent Health (NYSE:EVH) Coverage Initiated by Analysts at Needham & Company LLC

Needham & Company LLC began coverage on shares of Evolent Health (NYSE:EVH) in a research report sent to investors on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $15.00 target price on the technology company’s stock.

EVH has been the subject of several other reports. JPMorgan Chase & Co. decreased their target price on shares of Evolent Health from $45.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, November 22nd. KeyCorp initiated coverage on shares of Evolent Health in a report on Friday, October 11th. They issued an “overweight” rating and a $35.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $20.00 target price on shares of Evolent Health in a report on Tuesday, November 12th. Barclays reduced their price target on Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Finally, BTIG Research lowered their price objective on Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $23.92.

Evolent Health Stock Down 0.2 %

EVH opened at $12.57 on Friday. The company has a market capitalization of $1.47 billion, a PE ratio of -13.81 and a beta of 1.45. The business has a 50-day moving average of $13.13 and a 200-day moving average of $21.09. Evolent Health has a fifty-two week low of $10.53 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Covestor Ltd increased its position in shares of Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC grew its stake in shares of Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after purchasing an additional 1,556 shares during the last quarter. Quarry LP acquired a new stake in shares of Evolent Health in the second quarter valued at approximately $32,000. Canada Pension Plan Investment Board bought a new position in Evolent Health in the 2nd quarter worth approximately $61,000. Finally, Quest Partners LLC bought a new position in Evolent Health in the 2nd quarter worth approximately $87,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.